E-viri
Odprti dostop
-
SHIOTA, KENZO; MIKI, FUMIO; KAWAI, MICHIHIDE; KATO, YASUMICHI; SAITO, AKIRA; TOMIZAWA, MASUMI; NAGAHAMA, FUMIO; NAKABAYASHI, TAKEHITO; KAGAMI, YUICHI; WATANABE, AKIRA; OIZUMI, KOTARO; KONNO, KIYOSHI; TAKEDA, HAJIMU; KAWASHIMA, SHIRO; SEKINE, OSAMU; AOKI, NOBUKI; YAMASAKU, FUSANOSUKE; SUZUKI, YASUTOSHI; SHIMIZU, KIHACHIRO; FUJII, TOSHIHIRO; MURAKI, RYOICHI; IMADAKA, KUNIO; TAKIZUKA, HISASHI; NAKANO, MASATO; OKAYAMA, KENICHI; KANAI, YOSHICHIKA; OKUI, SHINJI; KATSU, MASATAKA; MASHIMO, KEIMEI; KUNII, OTOHIKO; FUKAYA, KAZUFUTO; UEDA, YASUSHI; SAITO, ATUSHI; NAKAGAWA, KEIICHI; WATANABE, KENTARO; SUZUKI, TATSUO; MOTOJIMA, SHINJI; KABE, JUNZABURO; SHIMADA, KAORU; INAMATSU, TAKASHI; TANIMOTO, HIROICHI; ARAI, SHINGO; KITAMOTO, OSAMU; KOBAYASHI, HIROYUKI; IKEMOTO, HIDEO; WATANABE, KAZUYOSHI; FUKUSHIMA, KOHKICHI; YAMAZAKI, RYUICHIRO; URIHARA, MAKIO; HASEGAWA, HIDEYUKI; KOHNO, MICHINORI; HIGASHI, FUYUHIKO; FUJIMORI, IPPEI; OYAMA, KAORU; SHIMIZU, RYUSAKU; GOTO, YUKIO; ONUMA, MASARU; YAMAMOTO, TOSHIYUKI; KITAURA, SABURO; KAN, SAKAE; MAEKAWA, NOBUO; NAKANISHI, MICHIYASU; YAMADA, EIICHI; OKUBO, HIROSHI; OKAMOTO, YURUKO; GO, KYOSHU; UBA, FUMIHIKO; UEDA, YOSHIHIRO; MAEHARA, KEIGO; MAKINO, JUNKO; NISHIZAWA, NATSUO; KAWAMURA, SHOICHI; YAMAGUCHI, SAKIMORI; TSUBURA, EIRO; KAWANO, MICHIAKI; KAWANO, TOMOHIRO; SOEJIMA, RINZO; TANO, YOSHIHIKO; MIZOGUCHI, DAISUKE; FUJII, CHIAKI; KIKUCHI, TAKESHI; SAWAE, YOSHIRO; HARA, KOHEI; SAITO, ATSUSHI; NAKATOMI, MASAO; NASU, MASARU; MORI, NOBUOKI; HORIUCHI, NOBUHIRO; IZUMIKAWA, KINICHI; TSUTSUMI, TSUNEO; TAKESHITA, JUNICHIRO; OKA, ROKUSHI; YOSHIO, KOJI; NAKANO, MASAMOTO; IKEBE, AKIRA; HAYASHIDA, MASAFUMI; ISHIKAWA, HISASHI; IWASAKI, HIROMARO; SUZUKI, HIROSHI; IWASAKI, HARUKO
CHEMOTHERAPY, 1978, Letnik: 26, Številka: 6Journal Article
For the purpose of comparison of the therapeutic effects and side effects between Apalcillin (APPC) and Carbenicillin (CBPC), a comparative clinical study was carried out in 142 patients with chronic respiratory tract infections at 31 institutions in Japan. Either of APPC or CBPC was assigned to each patient at random. Administration was performed by intravenous drip infusions for a fixed period of 14 days and the daily dosage was fixed at 2g (APPC) or 4 g (CBPC). A committee consisting of several physicians who had not been informed of the name of actually given drug, made a judgement on the severity, therapeutic results and presence or absence of side effects in each patient based on the detailed subjective and objective symptoms, laboratory findings and chest X-ray films. Subsequently, the key code for the drug administered to each patient was opened and a statistical analysis was carried out by a comparison between two groups (APPC group and CBPC group) with respect to background factors, clinical effectiveness, bacteriological effectiveness, degree of improvement and side effects. Out of 142 cases originally admitted to the trial, 16 cases were excluded bacause of failure to meet the initially established protocol and 126 cases (67 from APPC group and 59 from CBPC group) were used for the analysis of effectiveness while the analysis of side effects was done in 141 cases (75 from APPC group and 66 from CBPC group). It was indicated that there was no significant difference between the two groups regarding background factors except body weight, PaCO2 and ESR. Clinical effects of APPC were good in 40 cases, fair in 7 cases, poor in 19 cases and unknown in 1 case and those of CBPC were excellent in 3 cases, good in 32 cases, fair in 15 cases, poor in 7 cases and unknown in 2 cases. There was no statistically significant difference between the both groups concerning clinical effectiveness, bacteriological effectiveness and the degree of improvement. As to the incidence of side effects, no statistically significant difference was observed between the both groups.
